Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NINJA P-2: Nintedanib after resection of NSCLC in patients with IPF
jRCT1061220064Phase 2Recruiting
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nintedanib in idiopathic pulmonary fibrosis (IPF) and non-small cell lung cancer (NSCLC). Primary endpoint: Percentage of patients who remained on study drug by 26 weeks. Started Jan 2023; status: recruiting.
02
Drugs
nintedanib
03
Conditions
idiopathic pulmonary fibrosis (IPF)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT1061220064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1061220064.